Investigating treatments for inherited retinal degeneration caused by rhodopsin mutations
Pharmacological studies of rhodopsin metabolism
This study is looking at how certain genetic changes in a protein important for vision can cause eye problems in people with retinitis pigmentosa, and it’s testing new and existing medications to see if they can help protect vision in mice with this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10886562 on NIH RePORTER |
What this research studies
This research focuses on understanding how genetic mutations in rhodopsin, a visual pigment, lead to photoreceptor death in retinitis pigmentosa (RP). The team aims to develop small molecule drugs that can stabilize the structure of misfolded rhodopsin or promote the degradation of these misfolded proteins. Using a mouse model of RP, they will test the effectiveness and safety of two promising compounds, including a novel chaperone and an FDA-approved drug with anti-inflammatory properties. Advanced imaging and electrophysiology techniques will be employed to assess the impact on retinal structure and visual function.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with retinitis pigmentosa, particularly those with mutations affecting rhodopsin.
Not a fit: Patients with forms of blindness not related to rhodopsin mutations or retinitis pigmentosa may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective pharmacological treatments that preserve vision in patients with retinitis pigmentosa.
How similar studies have performed: Previous research has shown promise in targeting misfolded proteins in other conditions, suggesting potential success for this novel approach.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Chen, Yuanyuan — University of Pittsburgh at Pittsburgh
- Study coordinator: Chen, Yuanyuan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.